Who makes semaglutide and tirzepatide?
Semaglutide is a medication developed by Novo Nordisk, [1] while tirzepatide is a product of Eli Lilly and Company, [2] though licensed to various firms for manufacturing, distribution and sale, e.g. Eli Lilly distributes tirzepatide under the trade name Mounjaro.
Why switch from semaglutide to tirzepatide?
Research and anecdotal reports suggest that some patients may benefit from switching to tirzepatide due to potential differences in efficacy and side effect profiles. However, individual patient experiences can vary, and it's crucial to consult with a healthcare professional before making any changes to your treatment plan. [3]
How does tirzepatide compare with semaglutide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist, which means it targets not one, but two pathways involved in glucose metabolism. This may provide a more comprehensive therapeutic effect compared to semaglutide, a GLP-1 receptor agonist. Nevertheless, the long-term efficacy and safety of tirzepatide in patients previously treated with semaglutide are still being studied. [4]
Can I self-switch from semaglutide to tirzepatide, or must I consult my doctor?
It is essential to consult with your healthcare provider before making any changes to your treatment plan. Your doctor can help you weigh the benefits and risks of switching medications, especially considering any potential interactions with other medications or health conditions you may have. [5]
What are the side effects of tirzepatide compared to semaglutide?
While tirzepatide and semaglutide share some common side effects, such as nausea and injection site reactions, the former may have a more favorable tolerability profile due to its ability to act on two glucagon-like peptide receptors. Nonetheless, it's crucial to discuss the potential risks and benefits with your doctor before starting or switching to any new medication. [6]
When does the patent for semaglutide expire?
According to publicly available data from DrugPatentWatch.com, the patents for semaglutide are set to expire in various countries by 2039, though this timeline is subject to change based on patent extensions, renewals, or litigation. [7]
What are the pricing differences between semaglutide and tirzepatide?
Prices for both medications can vary depending on your location, insurance coverage, and the pharmacy or supplier you use. It's recommended to consult with your healthcare provider or insurance provider to determine the expected costs and any potential out-of-pocket expenses.
References:
[1] https://www.novonordisk.com/
[2] https://www.lilly.com/
[3] ClinicalTrials.gov: A Phase 3 study to assess the efficacy and safety of tirzepatide in patients with type 2 diabetes, NCT04034251
[4] Eli Lilly and Company. (2022). Mounjaro (tirzepatide) injection, for intravenous use, and for subcutaneous use.
[5] Mayo Clinic. (2022). Diabetes medications.
[6] European Medicines Agency (EMA). (2022). Mounjaro (tirzepatide) – EPAR.
[7] DrugPatentWatch.com. (2023). Semaglutide.